Simris Group advances two amanitin-based ADC programs toward the clinic
Simris Group AB confirms its strategy to develop amanitin-derived novel payloads to overcome treatment resistance in liquid and solid tumors. With strengthened specialist leadership, it will advance two proprietary Antibody-Drug Conjugate programs toward clinical development.